Clearmind Medicine Inc (NASDAQ:CMND) saw its shares surge 95% in premarket trading on Friday after the company announced publication of a Japanese patent application related to its MEAI-based depression treatment.
The clinical-stage biotechnology firm disclosed that the published application covers its proprietary compositions containing 5-Methoxy-2-aminoindan, commonly abbreviated MEAI. The company describes MEAI as a non-hallucinogenic molecule developed for the treatment of depression.
In its statement, Clearmind characterized the Japanese filing as an addition to an intellectual property portfolio that already includes multiple granted patents and pending applications across jurisdictions. The company said the filing strengthens its IP position for MEAI-based compositions.
Clearmind positions MEAI as an alternative approach to both traditional antidepressants and treatments derived from psychedelic compounds. The company highlighted limitations of current therapies - primarily selective serotonin reuptake inhibitors and other conventional antidepressants - noting issues such as delayed onset of action, adverse side effects, and high rates of treatment resistance.
The company also provided market context for the filing. Clearmind cited an estimate of roughly 3 million diagnosed cases of Major Depressive Disorder in Japan. It further referenced projected global market size ranges for anxiety and depression treatments of approximately $16 billion to $22.65 billion in 2025, expanding to roughly $19 billion to $30 billion by 2030-2031.
Beyond depression, Clearmind said it is broadening its MEAI-based development efforts. Ongoing research areas named by the company include alcohol use disorder, metabolic disorders such as weight loss, and other mental health conditions. The firm stated that its intellectual property portfolio now covers multiple jurisdictions, consistent with continued international filings.
Context and implications
The patent publication in Japan represents a regulatory and commercial milestone for Clearmind's MEAI program, according to the company's disclosures. The premarket stock reaction reflects investor attention to intellectual property updates that can underpin clinical-stage programs, but the company did not disclose new clinical data or regulatory approvals in its announcement.
The firm's characterization of MEAI as non-hallucinogenic and as an alternative to both conventional antidepressants and psychedelic-based therapies is part of its positioning for the molecule across the stated indications.
Market data
The company reported the Japanese application publication and reiterated its ongoing pipeline expansion; no additional numeric operational or clinical results were provided in the announcement.